ADVANCED SOLID TUMOURS

This early-stage study tests a new drug called SIM0610 in about 260 adults with advanced solid tumors (e.g., lung, colorectal, head and neck, liver cancer) that have spread. The main goals are to check the drug's safety and find the right dose, while also looking for signs that i…

This trial tests a new drug, UCB4594, designed to help the immune system attack cancer cells by targeting a protein called HLA-G found on many tumors. It is for people with advanced solid cancers that have not responded to standard treatments. The study aims to find the safest do…

This study tests a new drug called LM-168, alone or with another drug toripalimab, in people with advanced solid tumours that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumours. About 87 adults w…

This study tests a new drug called PYX-201 combined with pembrolizumab (a standard immunotherapy) in people with advanced solid tumors that have not responded well to other treatments. The main goals are to find the safest dose and see if the combination can shrink tumors or slow…

This study tests a new drug called EBC-129, given alone or with another drug (pembrolizumab), in people with advanced solid tumours that have stopped responding to standard treatments. The main goal is to check safety and find the best dose. About 98 adults will take part.

This early-stage study tests a new drug called AZD9592, alone or with other cancer treatments, in people with advanced solid tumors (lung, head & neck, or colorectal cancer that has spread). The main goals are to check safety, find the right dose, and see if it shrinks tumors. Ab…

This early-stage study tests a new drug called RC220 given with a standard chemotherapy (doxorubicin) in adults with advanced solid tumors. The goal is to find a safe dose and see if RC220 can protect the heart from doxorubicin's side effects. About 53 people will take part.